Resistance phenotypes and susceptibility of contemporary Serratia isolates in the university hospital of Crete, Greece

References

• European Centre for Disease Prevention and Control. Annual epidemiological report 2012: Reporting on 2010 surveillance data and 2011 epidemic intelligence data, Stockholm, Sweden; 2012. http://ecdc.europa.eu/en/publications/Publications/Annual-Epidemiological-Report-2012.pdf.
   Google Scholar
• Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51:S81–S87.
   PubMed Web of Science ®Google Scholar
• Samonis G, Vouloumanou EK, Christofaki M, et al. Serratia infections in a general hospital: characteristics and outcomes. Eur J Clin Microbiol Infect Dis. 2011;30:653–660.
   PubMed Web of Science ®Google Scholar
• Voelz A, Muller A, Gillen J, et al. Outbreaks of Serratia marcescens in neonatal and pediatric intensive care units: clinical aspects, risk factors and management. Int J Hyg Environ Health. 2010;213:79–87.
   PubMed Web of Science ®Google Scholar
• Yoon HJ, Choi JY, Park YS, et al. Outbreaks of Serratia marcescens bacteriuria in a neurosurgical intensive care unit of a tertiary care teaching hospital: a clinical, epidemiologic, and laboratory perspective. Am J Infect Control. 2005;33:595–601.
   PubMed Web of Science ®Google Scholar
• Maltezou HC, Tryfinopoulou K, Katerelos P, et al. Consecutive Serratia marcescens multiclone outbreaks in a neonatal intensive care unit. Am J Infect Control. 2012;40:637–642.
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, et al. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011). Diagn Microbiol Infect Dis. 2014;78:443–448.
   PubMed Web of Science ®Google Scholar
• Laupland KB, Parkins MD, Gregson DB, et al. Population-based laboratory surveillance for Serratia species isolates in a large Canadian health region. Eur J Clin Microbiol Infect Dis. 2008;27:89–95.
   PubMed Web of Science ®Google Scholar
• Herra C, Falkiner F. Serratia marcescens. In Antimicrobial therapy. http://www.antimicrobe.org/b26.asp.
   Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement, Wayne, Pa; 2015.
   Google Scholar
• Stock I, Grueger T, Wiedemann B. Natural antibiotic susceptibility of strains of Serratia marcescens and the S. liquefaciens complex: S. liquefaciens sensu stricto, S. proteamaculans and S. grimesii. Int J Antimicrob Agents. 2003;22:35–47.
   PubMed Web of Science ®Google Scholar
• Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis. 1997;24 Suppl 1:S67–S73.
   PubMed Web of Science ®Google Scholar
• Yu VL, Oakes CA, Axnick KJ, et al. Patient factors contributing to the emergence of gentamicin-resistant Serratia marcescens. Am J Med. 1979;66:468–472.
   PubMed Web of Science ®Google Scholar
• Merkier AK, Rodriguez MC, Togneri A, et al. Outbreak of a cluster with epidemic behavior due to Serratia marcescens after colistin administration in a hospital setting. J Clin Microbiol. 2013;51:2295–2302.
   PubMed Web of Science ®Google Scholar
• Samonis G, Korbila IP, Maraki S, et al. Trends of isolation of intrinsically resistant to colistin Enterobacteriaceae and association with colistin use in a tertiary hospital. Eur J Clin Microbiol Infect Dis. 2014;33:1505–1510.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Maraki S, Karageorgopoulos DE, et al. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int J Antimicrob Agents. 2010;35:497–499.
   PubMed Web of Science ®Google Scholar
• Mlynarczyk A, Szymanek K, Sawicka-Grzelak A, et al. CTX-M and TEM as predominant types of extended spectrum beta-lactamases among Serratia marcescens isolated from solid organ recipients. Transplant Proc. 2009;41:3253–3255.
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Prescribing information for tygacil (tigecycline); 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf.
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters; 2016. Available from: http://www.eucast.org
   Google Scholar
• Barry J, Brown A, Ensor V, et al. Comparative evaluation of the VITEK 2 Advanced Expert System (AES) in five UK hospitals. J Antimicrob Chemother. 2003;51:1191–1202.
   PubMed Web of Science ®Google Scholar
• Sanders CC, Peyret M, Moland ES, et al. Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol. 2000;38:570–574.
   PubMed Web of Science ®Google Scholar
• Poulou A, Grivakou E, Vrioni G, et al. Modified CLSI extended-spectrum beta-lactamase (ESBL) confirmatory test for phenotypic detection of ESBLs among Enterobacteriaceae producing various beta-lactamases. J Clin Microbiol. 2014;52:1483–1489.
   PubMed Web of Science ®Google Scholar
• Polsfuss S, Bloemberg GV, Giger J, et al. Practical approach for reliable detection of AmpC beta-lactamase-producing Enterobacteriaceae. J Clin Microbiol. 2011;49:2798–2803.
   PubMed Web of Science ®Google Scholar
• Tsakris A, Poulou A, Pournaras S, et al. A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J Antimicrob Chemother. 2010;65:1664–1671.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29:321–347.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Legakis NJ, Triarides N, et al. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016;47:269–285.
   PubMed Web of Science ®Google Scholar
• Maraki S, Samonis G, Karageorgopoulos DE, et al. In vitro antimicrobial susceptibility to isepamicin of 6296 Enterobacteriaceae clinical isolates collected at a tertiary care university hospital in Greece. Antimicrob. Agents Chemother. 2012;56:3067–3073.
   PubMed Web of Science ®Google Scholar
• Iosifidis E, Farmaki E, Nedelkopoulou N, et al. Outbreak of bloodstream infections because of Serratia marcescens in a pediatric department. Am J Infect Control. 2012;40:11–15.
   PubMed Web of Science ®Google Scholar
• Chen YH, Hsueh PR, Badal RE, et al. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect. 2011;62:280–291.
   PubMed Web of Science ®Google Scholar
• Andrasevic AT, Dowzicky MJ. In vitro activity of tigecycline and comparators against Gram-negative pathogens isolated from blood in Europe (2004–2009). Int J Antimicrob Agents. 2012;39:115–123.
   PubMed Web of Science ®Google Scholar
• Mahlen SD. Serratia infections: from military experiments to current practice. Clin Microbiol Rev. 2011;24:755–791.
   PubMed Web of Science ®Google Scholar
• Oteo J, Ortega A, Bartolome R, et al. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem. Antimicrob Agents Chemother. 2015;59:3406–3412.
   PubMed Web of Science ®Google Scholar
• Lin X, Hu Q, Zhang R, et al. Emergence of Serratia marcescens isolates possessing carbapenem-hydrolysing beta-lactamase KPC-2 from China. J Hosp Infect. 2016;94:65–67.
   PubMed Web of Science ®Google Scholar
• Zhang R, Cai JC, Zhou HW, et al. Genotypic characterization and in vitro activities of tigecycline and polymyxin B for members of the Enterobacteriaceae with decreased susceptibility to carbapenems. J Med Microbiol. 2011;60:1813–1819.
   PubMed Web of Science ®Google Scholar
• Silva KE, Cayo R, Carvalhaes CG, et al. Coproduction of KPC-2 and IMP-10 in carbapenem-resistant Serratia marcescens isolates from an outbreak in a Brazilian Teaching Hospital. J Clin Microbiol. 2015;53:2324–2328.
   PubMed Web of Science ®Google Scholar
• Suh B, Bae IK, Kim J, et al. Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss. Antimicrob Agents Chemother. 2010;54:5057–5061.
   PubMed Web of Science ®Google Scholar